Columnar cell lesions of the breast include a morphologic spectrum of simple columnar cell change, columnar cell hyperplasia, columnar cell hyperplasia with atypia and ductal carcinoma in situ of micropapillary/cribriform type. Invasive carcinomas of low grade are often seen in association with this spectrum. The biologic significance of these lesions that are commonly found on breast biopsies is unknown. Three cases of formalinfixed, paraffin-embedded breast tissues, each displaying the entire spectrum of columnar cell lesions through ductal carcinoma in situ and including foci of invasive carcinoma were microdissected at multiple sites to evaluate neoplasia progression. Minute tissue targets were microdissected (4-8/case) from unstained 4-lm thick recut paraffin sections and included non-neoplastic breast and sites of columnar cell change, hyperplasia, atypia, ductal carcinoma in situ and invasive carcinoma. Allelic imbalance for a broad panel of microsatellite markers in proximity to known tumor suppressor genes was quantitated using automated polymerase chain reaction/gel electrophoresis. Genomic loci evaluated 1p, 3p, 5q, 9p, 9q, 10q, 17p, 17q, 19q, 22q. The presence, topographic relationship and time course of mutational damage was correlated with columnar morphologic features. Detailed allelic imbalance information was obtained from each microdissection tissue target producing a detailed fingerprint of mutational damage in each case. Allelic damage was targeted predominately at 9q, 10q, 17p and 17q. Simple columnar cell change was without mutational changes and only present in one case of columnar cell hyperplasia. The remainder of the cases all show progressive accumulation of allelic damage in columnar cell changes with atypia, ductal carcinoma in situ and invasive carcinoma. The fractional mutation percentage increased progressively from columnar cell hyperplasia through invasive carcinoma. Low level of allelic imbalance was demonstrable in columnar cell lesions by the microdissection approach. A gradient of progressive mutational change could be delineated in each case manifesting allelic loss damage. Allelic loss damage appeared to preferentially target loci at 9q, 10q, 17p and 17q. The findings are consonant with the hypothesis that a select group of atypical columnar cell lesions are morphologic precursors to invasive carcinoma. Integrated molecular pathology analysis used here can help define the significance of columnar cell lesions and its role in breast cancer tumorigenesis on an individual patient basis.
Breast terminal duct epithelium which assumes a columnar morphologic appearance has been recognized for decades, and has been referred to by a variety of names, including abnormal involution, cystic lobules, atypical cystic lobules, atypical lobules, hyperplastic unfolded lobules, hyperplastic lobules, columnar alteration with prominent apical snouts and secretions and enlarged lobular units with columnar alteration. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Illustrations of the columnar alterations in published papers and textbooks reveal a transformation of the terminal ductlobular unit from a low cuboidal epithelium to a tall columnar epithelium that is often cystically dilated to some degree. This altered cell type, or columnar cell change may be associated with a normal lobular size, a lobule which is enlarged or a lobule which is enlarged and dilated. Invariably, low magnification reveals a distinct eye-catching blue color to the columnar arrangement as a manifestation of the increased numbers of cells per lobular unit area.
A spectrum of epithelial pathologies composed of columnar cell lesions frequently coexist. In addition to the simple columnar cell change of the lobule, there may be columnar cell hyperplasia with or without atypia, and atypia may also manifest as 'flat atypia' which is cytological high-grade atypia without abundant epithelial proliferation. 17 Flat atypia likely represents a morphologic form of atypical duct epithelial hyperplasia. One-third of follow-up excisions of flat atypia show more serious pathology, an incidence analogous to excisional follow-up of atypical duct epithelial hyperplasia. 18 Epithelial thickening, or piling up in the pattern of hyperplasia may ensue. Atypia of cytologic or architectural type (club-shaped micropapillae, Roman arches) may accompany hyperplastic epithelium. The duct carcinoma in situ (DCIS) most commonly seen in association is the low grade, micropapillary/cribriform type.
The spectrum of changes seen within columnar cell lesions implies an association of progression to atypia/carcinoma. To date there are no molecular studies that support such a hypothesis. The goal of this study is to examine the above-mentioned morphologic spectrum in order to determine if there is a molecular spectrum of abnormalities that would support a molecular progression from columnar cell change through DCIS and invasive carcinoma.
We chose to employ loss of heterozygosity (LOH) studies to examine for microsatellite alterations in each of the morphologic entities of columnar change, columnar hyperplasia, columnar atypia, ductal carcinoma in situ and invasive carcinoma. Evidence of a molecular precursor status would demonstrate LOH (an informative sample) and that specific LOH would necessarily be present in subsequent recognized putative morphologic precursors to carcinoma as well as in the carcinoma.
Materials and methods
Ten cases of formalin-fixed, paraffin-embedded breast tissues that showed columnar alterations were used. Seven of the cases displayed the entire spectrum of columnar cell change through DCIS, and included foci of invasive carcinoma (Figures 1-6 ).
All cases were microdissected with a dissecting microscope at multiple sites to evaluate for neoplas- Allelic imbalance for a broad panel of microsatellite markers in proximity to known tumor suppressor genes was quantitated using automated PCR/gel electrophoresis. Genomic loci evaluated 1p, 3p, 5q, 9p, 9q, 10q, 17p, 17q, 19q, 22q. A total of 20 specific microsatellite regions from these 10 chromosomal sites were evaluated ( Table 1) . The percentage of material showing mutation was always greater than 50%. Of 43 sites, 1040 total tests were performed with 277 noninformative tests.
The presence, topographic relationship and time course of mutational damage was correlated with columnar morphologic features.
Tumor suppressor gene loss was based on determination of LOH for informative loci situated within or adjacent to specific genes of interest. DNA polymorphisms were in the form of polymorphic microsatellites with polymerase chain reaction (PCR) primers based on cytogenetic location and GenBank references as follows: Microdissected tissue was PCR amplified with flanking oligonucleotides bearing fluorescent labels designed for GeneScan fragment analysis (Applied Biosystems). PCR products were separated by capillary electrophoresis (ABI 310, Applied Biosystems). In all cases, microdissected normal samples were run in parallel, serving as an internal negative control. To control for allelic dropout due to insufficient template, all microdissected normal tissue samples were taken to be no larger in size and to contain no more cells than the smallest microdissected lesional sample. All such normal internal controls were required to demonstrate allelic balance as defined below. Fluorescent labeled oligonucleotide primers were employed for quantitative determination of allelic imbalance based on the peak height ratio of polymorphic microsatellite alleles. Postamplification products were electrophoresed and relative fluorescence determined for individual allele peak height (GeneScan ABI3100, Applied Biosystems, Foster City, CA, USA). The ratio of peaks was calculated by dividing the value for the shorter sized allele by that of the longer sized allele (Figure 4) . Thresholds for significant allelic imbalance were determined beforehand in extensive studies using normal (nonneoplastic) specimens representing each unique pairing of individual alleles for every marker used in the panel. Peak height ratios falling outside of two s.d. beyond the mean for each polymorphic allele pairing were assessed as showing significant allelic imbalance.
Normal microdissected tissue samples were first evaluated for informative status with respect to individual alleles. When a particular microsatellite marker in a normal tissue sample manifested only a single peak, the patient was designated as noninformative for that marker. For informative subjects with respect to a specific marker, alleles were assessed as being in balance when the ratio of the individual allele peaks fell within two s.d. of the average generated from a large series of nonneoplastic microdissected tissue samples for subjects with the same pairing of specific polymorphic alleles.
Results
Detailed allelic imbalance information was obtained from each microdissected tissue target producing a detailed fingerprint of mutational damage in each case. The overall results are summarized in (Tables 2-4) .
A total of 10 normal lobules had no LOH from normal tissues or from tissues with carcinoma on the same slide. Two out of two cases of columnar cell change had no LOH. Two of the three hyperplastic columnar lesions cases had LOH at 9q22.1 and 10q23.31. Atypical hyperplasia of columnar cell type, DCIS and invasive carcinoma showed LOH in 10/11 cases. The maximal fractional mutation percentages increased progressively from simple columnar cell change (0%), to columnar cell hyperplasia (15%), atypical columnar cell hyperplasia(20%), DCIS (36%) and invasive carcinoma (40%) ( Table 3 ).
Discussion
Columnar cell lesions can be divided into two broad categories: columnar cell change and columnar cell hyperplasia. Each category has a subcategory of 'with atypia'. In the broadest sense, we consider the atypical categories to be viewed as atypical duct epithelial hyperplasia. A summary of histopathologic features 17 and mutational changes are summarized in Table 4 . CCH, columnar cell hyperplasia; ACCH, atypical columnar cell hyperplasia; DCIS, ductal carcinoma in situ; IC, invasive carcinoma.
Molecular alterations in columnar cell lesions DJ Dabbs et al
Columnar cell lesions are discovered on mammograms because they are associated with calcifications of the calcium phosphate type. At Magee-Women's Hospital, columnar cell alterations rank fifth as the pathologic finding associated with mammographic calcifications behind fibrocystic change, fibroadenoma, DCIS and sclerosing adenosis.
Mutational analysis by LOH in this study validates the morphologic spectrum impression of a kinship within the family of columnar alterations. A low level of allelic imbalance was demonstrable in columnar cell lesions using the microdissection approach. A gradient of progressive mutational change could be delineated in each case manifesting allelic loss damage. Allelic loss damage appeared to preferentially target loci at 9q, 10q, 17p and 17q. Mutational change in hyperplastic and atypical lesions are commonly seen in DCIS and invasive carcinoma. The LOH patterns seen in atypical columnar cell lesions are also demonstrated in DCIS and invasive carcinoma, consistent with molecular neoplastic progression. The findings are consonant with the hypothesis that atypical columnar cell lesions are morphologic precursors to invasive carcinoma.
Biomarker studies of estrogen and progesterone (ER/PR) receptors, 8, 19 -bcl-2, 19 CyclinD1 22 on columnar cell alterations have demonstrated alterations compared to normal lobules. Columnar cell lesions routinely display strong and diffuse ER/PR compared to the focal and variable immunostaining of surrounding lobules. Upregulation of ER suggests the possibility that columnar alterations have escaped normal ER regulation and that it may represent one avenue to an ER-dependent pathway to carcinoma. Accelerated growth fractions of proliferative and atypical columnar alterations manifested by increased Ki-67 indices, cyclin D1 expression and antiapoptosis signaling with bcl-2 are supportive of this hypothesis. Oyama 8 noted the close geometric proximity of cystic lobules of columnar type, atypical proliferations and DCIS and concluded that the atypical cystic lobules were an early phase in the pathway to DCIS.
There are several studies in the literature that address molecular evolution of preneoplastic breast proliferations, but they do not specifically address the columnar line of proliferation.
O'Connell et al 23 found LOH in 50% of duct epithelial hyperplasia with and without atypia, and in 80% of DCIS. Lakhani et al 24 observed an LOH rate of 55% at 17p (D17S796) and 16q (D16S413). Chuaqui et al 25 using 11q13 found only 9% of cases had LOH in atypical hyperplasia and 27% in DCIS. None of the low-grade DCIS cases in his study showed LOH at the 11q13 locus, while high-grade DCIS had LOH in 35% of cases. We did not examine the 11q13 locus in this study.
O'Connell et al 26 in a study of 399 premalignant cases found that 37% of usual hyperplasia and 42% of atypical hyperplasias show LOH at one locus, while finding 70% of noncomedo and 79% of comedo DCIS showing at least one loss. Identical percentages of preneoplastic cases shared LOH with synchronous cancers.
Papillary tumors of the breast also show LOH in benign, atypical and in situ carcinomas. 27 Studies by Amari et al, 28 Washington et al 29 and Maitra et al 30 showed frequent losses at 3p (multiple discontinuous regions), and 8p, 16q, 17q. Washington also discovered LOH of at least one type with fibrocystic change components, including apocrine metaplasia adjacent to tumors. In our study, we examined only normal appearing lobules adjacent to preneoplastic change and tumors, but did not find LOH at any of the 20 sites. Kaneko 31 demonstrated increasing frequencies of LOH in usual ductal hyperplasia from those without atypia through ADH.
Moinfar et al 15 studied 13 cases of 'flat atypia', referred to as 'clinging carcinoma', finding that 70% showed LOH at one or more of the loci and that these mutations were the same in DCIS and invasive carcinoma.
The 70% LOH rate that Moinfar found in the lesions of flat atypia is comparable to our findings in atypical epithelial hyperplasia.
To summarize, columnar cell lesions represent a spectrum from simple 'change' of terminal duct lobular epithelium to invasive carcinoma. Select atypical groups in this morphologic spectrum, observed by many for a long time, clearly display molecular abnormalities that progressively accumulate into those lesions that we recognize as DCIS. The 'early lesions' referred to by Oyama represent a particularly challenging focus. They are without molecular abnormalities and may represent nonobligate precursors to neoplasia. Systematic prospective follow-up of patients with columnar cell lesions would contribute immensely to our understanding of the natural history of this entity.
